Jan 28, 2013, 02.16 PM IST
Pharmaceutical company Glenmark's US subsidiary Glenmark Generics has received final approval from US Food and Drugs Administration for its abbreviated new drug application for Mupirocin Calcium Cream USP, 2 percent.
Pharmaceutical company Glenmark 's US subsidiary Glenmark Generics has received final approval from US Food and Drugs Administration for its abbreviated new drug application for Mupirocin Calcium Cream USP, 2 percent.
Mupirocin Calcium Cream is indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length) caused by bacteria such as S aureus and S pyogenes, Glenmark said on Monday.
The cream had US sales of USD 56.5 million for the year-ended Sept 2012, it added, citing IMS Health data.
Glenmark now has 83 products authorized for distribution in the US and a further 46 ANDAs are pending approval with the FDA.
Glenmark shares hit a high of Rs 534.80 in morning trade on Monday and at 9:45 hrs, it was up 0.5 percent at Rs 517.35.
Glenmark stock price
On December 05, 2013, at 12:28 hrs Glenmark Pharma was quoting at Rs 535.25, up Rs 10.55, or 2.01 percent. The 52-week high of the share was Rs 612.00 and the 52-week low was Rs 423.00.
The company's trailing 12-month (TTM) EPS was at Rs 15.41 per share as per the quarter ended September 2013. The stock's price-to-earnings (P/E) ratio was 34.73. The latest book value of the company is Rs 93.06 per share. At current value, the price-to-book value of the company is 5.75.
Action in Glenmark Pharma
Video of the day
Dec 4 2013, 16:28
- in Business
Dec 4 2013, 11:08
- in FII View
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.